TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$23.17 (+84.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Travere Therapeutics, Inc. grew revenue 77.1% to $591.33M over the twelve months to Jun 30, 2026.
Revenue
$591.33M
+77.1% vs. a year earlier
Operating income
-$40.46M
TTM Q2 2027
EPS, diluted
-$0.46
TTM Q2 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.72B
- P/E ratio
- –
- Price to sales
- 7.98
- Price to book
- 192.47
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $591.33M
- Net income
- -$43.46M
- EPS, diluted
- -$0.46
- Book value per share
- $0.26
- Diluted shares
- 93M
Fifteen years at a glance
Fiscal years 2011 to 2026 and trailing twelve months, USD
Revenue
$591.33M+77.1% YoY
Gross profit
$583.07M+80.2% YoY
Operating income
-$40.46M
Net income
-$43.46M
EPS, diluted
-$0.46
Free cash flow
–
Reported periodTrailing twelve months